Inter- and Intra-observer Reproducibility of Thyroid Fine Needle Aspiration Cytology: An investigation of Bethesda 2023 Using Immunohistochemical BRAFV600E Antibody
Open Access
- 1 October 2024
- journal article
- research article
- Published by Medknow in Journal of Cytology
- Vol. 41 (4) , 221-228
Abstract
Background: The Bethesda System for Reporting Thyroid Cytology (TBSRTC) recommended for the interpretation of needle aspiration cytology of the thyroid, is the most widely used worldwide. Studies have shown that the disagreement between observers, especially in the Bethesda III and IV diagnostic categories, is not insignificant at 10%–40%. In the TBSRTC 2023 version, some definitions were removed and simplified, and molecular pathology was proposed as a complement to cytopathology. The current availability of molecular tests is limited because they can be performed in a few centers and are expensive. Therefore, our study investigated intra- and inter-observer agreement according to TBSRTC 2023 using only immunohistochemically BRAFV600E antibodies. Materials and Methods: The study included 173 cases with aspiration cytology evaluated between 2019 and 2022. The immunohistochemical procedure applied BRAFV600E (RM8) monoclonal antibody to cell block sections. All slides were assessed and categorized by three different observers. Data were interpreted using Cohen’s kappa and Fleiss’s kappa test in the Statistical Package for Social Sciences Windows 2021 program. Results: For the applied RM8 antibody, sensitivity was 64.71% and specificity was 87.27%. In terms of diagnostic categories, inter-observer agreement was good for Bethesda II (K = 0.606) and moderate for Bethesda III (K = 0.429), Bethesda IV (K = 0.523), Bethesda V (K = 0,464), and Bethesda VI (K = 0.544), respectively. Conclusion: In conclusion, the study reveals that the 2023 version of TBSRTC provides improvement, especially in the categories of uncertain diagnosis, but is still insufficient to improve cytological diagnostic accuracy, at which point molecular analyses become even more important.Keywords
This publication has 20 references indexed in Scilit:
- Development of a Molecular Assay for Detection and Quantification of theBRAFVariation in Residual Tissue From Thyroid Nodule Fine-Needle Aspiration Biopsy SpecimensJAMA Network Open, 2021
- Low reproducibility of equivocal categories of the Bethesda System for Reporting Thyroid Cytology makes the associated risk of malignancy specific to the diagnostic centerEndocrine, 2021
- Multicentre validation of a microRNA-based assay for diagnosing indeterminate thyroid nodules utilising fine needle aspirate smearsJournal of Clinical Pathology, 2016
- Use of BRAF v600e immunocytochemistry on FNA direct smears of papillary thyroid carcinomaCancer Cytopathology, 2015
- VE1 Antibody Is Not Highly Specific for the BRAF V600E Mutation in Thyroid Cytology Categories With the Exception of Malignant CasesAmerican Journal of Clinical Pathology, 2015
- Malignancy risk and reproducibility associated with atypia of undetermined significance on thyroid cytologySurgery, 2014
- Analysis of immunocytochemical and molecular BRAF expression in thyroid carcinomas: A cytohistologic institutional experienceCancer Cytopathology, 2014
- Value of immunohistochemistry in the detection of BRAFV600E mutations in fine‐needle aspiration biopsies of papillary thyroid carcinomaCancer Cytopathology, 2013
- The Bethesda System for Reporting Thyroid CytopathologyThyroid®, 2009
- Inter‐ and intraobserver reproducibility of thyroid fine needle aspiration cytology: an analysis of discrepant casesCytopathology, 2007